Login / Signup

A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis.

Ann LoganZsuzsanna NagyNicholas M BarnesAntonio BelliValentina Di PietroBarbara TavazziGiuseppe LazzarinoGiacomo LazzarinoLars BruceLennart I Persson
Published in: PloS one (2022)
EudraCT 2017-005065-47.
Keyphrases
  • open label
  • phase ii
  • amyotrophic lateral sclerosis
  • clinical trial
  • phase iii
  • phase ii study
  • double blind
  • study protocol
  • placebo controlled
  • randomized controlled trial
  • squamous cell carcinoma